1:54AM Optimer Pharma presents post-hoc subgroup analysis of DIFICID in adult cancer patients being treated for clostridium difficile-associated diarrhea had higher clinical cure rates, better sustained response and lower recurrence (OPTR) 13.90 : Co announces the presentation of results from a post-hoc subgroup analysis of the co's two large Phase 3 trials which demonstrated that cancer patients with Clostridium difficile-associated diarrhea had higher clinical cure rates, better sustained response and lower recurrence when treated with DIFICID tablets compared to oral vancomycin. In the overall combined population, patients with cancer had significantly lower cure and sustained response rates than patients without cancer. DIFICID was five times more likely than vancomycin to produce a clinical response and three times more likely to lead to a sustained response, while patients treated with vancomycin had a 2.6 fold greater risk of experiencing recurrence. Specifically, DIFICID provided superior response compared to vancomycin across all clinical endpoints studied: clinical response (97.3% vs. 87.5%), sustained response (83.6% vs. 61.3%) and disease recurrence (14.1% vs. 30.0%). Furthermore, cancer patients who were treated with DIFICID in the clinical studies had similar cure, recurrence and sustained response rates as non-cancer patients who received the drug, while cancer patients treated with vancomycin tended to have poorer outcomes than non-cancer patients. The overall safety profile was similar between the DIFICID and vancomycin treatment groups.
surf's up......crikey
